Dean J Kereiakes1, Stephen G Ellis2, Christopher Metzger3, Ronald P Caputo4, David G Rizik5, Paul S Teirstein6, Marc R Litt7, Annapoorna Kini8, Ameer Kabour9, Steven O Marx10, Jeffrey J Popma11, Robert McGreevy12, Zhen Zhang12, Charles Simonton12, Gregg W Stone10. 1. The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio. Electronic address: lindner@thechristhospital.com. 2. Cleveland Clinic, Cleveland, Ohio. 3. Wellmont Holston Valley Medical Center, Kingsport, Tennessee. 4. St. Joseph's Hospital Health Center, Liverpool, New York. 5. Scottsdale Healthcare, Scottsdale, Arizona. 6. Scripps Clinic, La Jolla, California. 7. Baptist Medical Center, Jacksonville, Florida. 8. Mount Sinai Medical Center, New York, New York. 9. Mercy St. Vincent's Medical Center, Toledo, Ohio. 10. New York Presbyterian Hospital, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York. 11. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 12. Abbott Vascular, Santa Clara, California.
Abstract
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized toBVS versus cobalt-chromium everolimus-eluting stents (EES). OBJECTIVES: This study sought to assess clinical outcomes through 3 years following BVS implantation. METHODS: Clinical outcomes from the ABSORB III trial were analyzed by randomized treatment assignment cumulative through 3 years, and between 1 and 3 years. RESULTS: The primary composite endpoint of target lesion failure through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (p = 0.06), and between 1 and 3 years in 7.0% versus 6.0% of patients, respectively (p = 0.39). TVMI through 3 years was increased with BVS (8.6% vs. 5.9%; p = 0.03), as was device thrombosis (2.3% vs. 0.7%; p = 0.01). In BVS-assigned patients, treatment of very small vessels (those with quantitatively determined reference vessel diameter <2.25 mm) was an independent predictor of 3-year TLF and scaffold thrombosis. CONCLUSIONS: In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906).
RCT Entities:
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES). OBJECTIVES: This study sought to assess clinical outcomes through 3 years following BVS implantation. METHODS: Clinical outcomes from the ABSORB III trial were analyzed by randomized treatment assignment cumulative through 3 years, and between 1 and 3 years. RESULTS: The primary composite endpoint of target lesion failure through 3 years occurred in 13.4% of BVS patients and 10.4% of EES patients (p = 0.06), and between 1 and 3 years in 7.0% versus 6.0% of patients, respectively (p = 0.39). TVMI through 3 years was increased with BVS (8.6% vs. 5.9%; p = 0.03), as was device thrombosis (2.3% vs. 0.7%; p = 0.01). In BVS-assigned patients, treatment of very small vessels (those with quantitatively determined reference vessel diameter <2.25 mm) was an independent predictor of 3-year TLF and scaffold thrombosis. CONCLUSIONS: In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906).
Authors: Gabriel T R Pereira; Alessio La Manna; Yasuhiro Ichibori; Armando Vergara-Martel; Bruno Ramos Nascimento; Abdul Jawwad Samdani; Davide Capodanno; Guido D'Agosta; Giacomo Gravina; Giuseppe Venuti; Corrado Tamburino; Guilherme F Attizzani Journal: Int J Cardiovasc Imaging Date: 2019-06-07 Impact factor: 2.357
Authors: Pawel Gasior; Yanping Cheng; Jinggang Xia; Gerard B Conditt; Jennifer C McGregor; Renu Virmani; Juan F Granada; Grzegorz L Kaluza Journal: Cardiol J Date: 2018-08-29 Impact factor: 2.737
Authors: Katherine Hsin-Yu Chau; Kevin F Kennedy; John C Messenger; Kirk N Garratt; Thomas M Maddox; Robert W Yeh; Ajay J Kirtane Journal: JAMA Cardiol Date: 2019-06-01 Impact factor: 14.676
Authors: Gregg W Stone; Takeshi Kimura; Runlin Gao; Dean J Kereiakes; Stephen G Ellis; Yoshinobu Onuma; Bernard Chevalier; Charles Simonton; Ovidiu Dressler; Aaron Crowley; Ziad A Ali; Patrick W Serruys Journal: JAMA Cardiol Date: 2019-12-01 Impact factor: 14.676